A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
Arizona Urology Specialists, Tucson, Arizona Los Angeles Cancer Network, Anaheim, California Providence Medical Group Oncology Santa Rosa, Santa Rosa, California Florida Urology Partners, Tampa, Florida Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana First Urology, Jeffersonville, Indiana Wichita Urology Group, Wichita, Kansas National Cancer Institute, Bethesda, Maryland Chesapeake Urology, Towson, Maryland XCancer Center Omaha/Urology Cancer Center, Omaha, Nebraska Garden Sate Urology, Morristown, New Jersey New Mexico Oncology Hematology Consultants Ltd, Albuquerque, New Mexico Duke Cancer Center, Durham, North Carolina Helios Clinical Research, LLC, Middleburg Heights, Ohio Toledo Clinical Cancer Center, Toledo, Ohio MidLantic Urology, Bala-Cynwyd, Pennsylvania Carolina Urologic Research Center, Myrtle Beach, South Carolina Urology Associates PC, Nashville, Tennessee Urology Clinics of North Texas, Dallas, Texas Houston Metro Urology, Houston, Texas Oncology Consultants, Houston, Texas Urology San Antonio, San Antonio, Texas University of Virginia Cancer Center, Charlottesville, Virginia Northwest Medical Specialties, Tacoma, Washington Puerto Rico
Pan American Center for Oncology Trials, LLC, San Juan, Rio Piedras Last updated February 2026